Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

dc.creatorNetea, Mihai G.
dc.creatorGiamarellos-Bourboulis, Evangelos J.
dc.creatorDomínguez-Andrés, Jorge
dc.creatorCurtis, Nigel
dc.creatorvan Crevel, Reinout
dc.creatorvan de Veerdonk, Frank L.
dc.creatorBonten, Marc
dc.date2020-08-03T16:52:30Z
dc.date2020-08-03T16:52:30Z
dc.date2020-05
dc.date.accessioned2023-09-28T19:56:52Z
dc.date.available2023-09-28T19:56:52Z
dc.identifierNETEA, M.G. et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell, [S.l.], v. 181, n. 5, p. 969-977, May 2020.
dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0092867420305079
dc.identifierhttp://repositorio.ufla.br/jspui/handle/1/42184
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9040841
dc.descriptionSARS-CoV-2 infection is mild in the majority of individuals but progresses into severe pneumonia in a small proportion of patients. The increased susceptibility to severe disease in the elderly and individuals with co-morbidities argues for an initial defect in anti-viral host defense mechanisms. Long-term boosting of innate immune responses, also termed “trained immunity,” by certain live vaccines (BCG, oral polio vaccine, measles) induces heterologous protection against infections through epigenetic, transcriptional, and functional reprogramming of innate immune cells. We propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.
dc.languageen_US
dc.publisherElsevier
dc.rightsrestrictAccess
dc.sourceCell
dc.subjectCOVID-19
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
dc.subjectTrained immunity
dc.titleTrained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection
dc.typeArtigo


Este ítem pertenece a la siguiente institución